Is There a Meaningful Serum Hepatitis B Virus DNA Cutoff Level for Therapeutic Decisions in Hepatitis B e Antigen-Negative Chronic Hepatitis B Virus Infection?

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3140310 20 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Is There a Meaningful Serum Hepatitis B Virus DNA Cutoff Level for
Therapeutic Decisions in Hepatitis B e Antigen-Negative Chronic
Hepatitis B Virus Infection?
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The diagnosis of hepatitis B e antigen (HBeAg)-negative chronic
hepatitis B indicating therapeutic intervention currently requires serum
hepatitis B virus (HBV) DNA >= 2,000 IU/mL. We evaluated the severity of
liver histology and the presence of histological indication for
treatment in patients with HBeAg-negative chronic HBV infection focusing
on those with low viremia and/or normal alanine aminotransferase (ALT).
In total, 399 patients with increased ALT and detectable serum HBV DNA
(chronic hepatitis B patients) and 35 cases with persistently normal ALT
and HBV DNA >2,000 IU/mL (inactive carriers) were included. Histological
indication for treatment (grading score >= 7 and/or stage >= 2 in
Ishak’s classification) was found in 91% (185/203), 82% (75/91), 75%
(47/63), and 62% (26/42) of chronic hepatitis B patients with HBV DNA
>= 200,000, 20,000-199,999, 2,000-19,999, and <2,000 IU/mL, respectively
(P < 0.001). Histological indication for treatment was more frequent in
chronic hepatitis B patients with persistently elevated ALT (86% or
275/321), but it was also found in 74% (58/78) of those with
transiently normal ALT (P = 0.025). All inactive carriers had HBV DNA
<20,000 IU/mL. Histological indication for treatment was present in 17%
(6/35) of inactive carriers always due to moderate (stage 2) fibrosis
without active necroinflammation. Conclusion: HBeAg-negative chronic HBV
patients with persistently or transiently increased ALT and HBV DNA >=
20,000 IU/mL almost always require therapeutic intervention, but
histological indications for treatment are also present in the majority
of such cases with HBV DNA < 20,000 and even < 2,000 IU/mL. In contrast,
minimal histological lesions are observed in the majority of
HBeAg-negative patients with persistently normal ALT and HBV DNA > 2,000
IU/mL, who may not require immediate liver biopsy and treatment but only
close follow-up. (HEPATOLOGY 2008;48:1451-1459.)
Έτος δημοσίευσης:
2008
Συγγραφείς:
Papatheodoridis, George V.
Manesis, Emanuel K.
Manolakopoulos,
Spilios
Elefsiniotis, Ioannis S.
Goulis, John
Giannousis,
John
Bilalis, Antonios
Kafiri, Georgia
Tzourmakliotis,
Dimitrios
Archimandritis, Athanasios J.
Περιοδικό:
Gastroenterologie a Hepatologie
Εκδότης:
Wiley
Τόμος:
48
Αριθμός / τεύχος:
5
Σελίδες:
1451-1459
Επίσημο URL (Εκδότης):
DOI:
10.1002/hep.22518
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.